NeuroMetrix Gets FDA Clearance for Quell Device
Neurometrix has received FDA clearance for a new smartphone-controlled version of Quell, its wearable for pain relief, the company announced last week.
Like its predecessor, the device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids. It’s worn around the calf.
“This 510(k) further advances Quell technology by allowing the device to be conveniently and safely controlled via a smartphone,” Dr. Shai Gozani, president and CEO of NeuroMetrix said in a statement. “It is a clear example of our unwavering commitment to creating the most clinically effective and technologically innovative wearable therapeutic solution for people suffering from chronic pain.”
Continuing to Innovate
Quell’s previous device, which was announced at CES 2015 and launched in July of last year, is smartphone-connected but the app can only be used to monitor the treatment, which is controlled automatically. It allows the user to track sleep as well as to track the neurotherapy the device delivers.
The new device, due out in March, will let the user directly control the nerve stimulation — they can turn it on and off and increase or decrease therapy levels, and toggle between two different validated therapy modes, one which feels like a constant vibration and one that feels more like a fast pulse.
The new device will track sleep more comprehensively, recording body position and movements while sleeping in addition to sleep time. FInally. it will also boast a longer battery life than the current device, which can last 30 hours on a charge. The company promises a 25 percent increase, which would be about 37 hours.
We're here for you.or call 800.204.6577